Table 2.
Tauopathies.
| References | Disease/stage | Protein | Localization/function | Detection antibody | Degree of oxidation in relation with age‐matched controls | Enzymatic activity | Total protein levels | Comments |
|---|---|---|---|---|---|---|---|---|
| Muntanéet al (74) | PiD | GFAP | Cytoskeleton | Anti‐AGE, anti‐CEL, anti‐CML, anti‐HNE, anti‐MDAL antibodies | ↑ | NA | NA | — |
| Ilieva et al (54) | PiD | Vesicle‐fusing ATPase | Energy metabolism | Anti‐DNPH antibody | ↑ | NA | NA | — |
| GFAP | Cytoskeleton | ↑ | NA | NA | — | |||
| Cathepsin D precursor isoform | Proteolysis | ↑ | NA | NA | — | |||
| Carbonyl reductase NADPH1 isoforms | Antioxidant response | ↑ | NA | NA | — | |||
| GAPDH | Glycolysis | ↑ | NA | NA | — | |||
| HSP 70 | Chaperone | ↑ | NA | NA | — | |||
| Martínez et al (65) | PSP | PGK‐1 | Glycolysis | Anti‐HNE antibody | ↑ | NA | = | — |
| Aldolasa A | Glycolysis | ↑ | NA | = | — | |||
| Santpere and Ferrer (103) | AGD PSP, early‐PSP | GFAP (anti‐AGE) | Cytoskeleton | Anti‐MDAL, anti‐AGE, anti‐CEL anti‐CML antibodies | ↑ Striatum in PSP ↑ Amygdala in AGD | NA | ↑ | — |
| Martínez et al (64) | FTLD‐tau FTLD‐U FTLD‐MND | GFAP | Cytoskeleton | Anti‐HNE antibody | ↑ | NA | ↑ | IHC Variations depending on the type of FTLD. More marked in FTLD‐tau |